CClinicalTrials.gg
CompletedNCT03274167Updated Sep 6, 2017

Efficacy of Gabapentin in Alcohol Dependency Treatment

A Phase 3 interventional study of Gabapentin 300mg and Placebo oral capsule in Alcohol Drinking and Heavy Drinking, sponsored by Chulalongkorn University. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by Chulalongkorn University · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study aims to study the effect of gabapentin on the number of alcohol drinking days and heavy drinking days in the Thai clinical alcohol-dependent population by using the double-blinded randomized controlled approach. One-hundred and twelve individuals with alcohol dependence were randomly assigned equally into two groups including treatment with gabapentin and placebo. Thirty-four patients (30.3%) completed the study protocol, i.e. treatment with gabapentin at least 300 mg per day or placebo orally once a day for twelve weeks. Pattern of alcohol drinking were obtained from the timelime followback. Drinking behaviors were compared between the two groups by poisson repeated measures model.

02

Conditions studied

  • Alcohol Drinking
  • Heavy Drinking
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • current diagnosis of alcohol dependence

Exclusion criteria

Exclusion Criteria:

  • having major psychiatric disorders including schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, or suicide risk based on a clinical interview by attending psychiatrist
  • receiving other medications not in the protocol of the study for any reasons or having history of using other substances including methamphetamine, heroin, cannabis, inhalants, mitragyna speciosa (or kratom in Thai), except tobacco based on self-report
  • having a medical disease, e.g. essential hypertension, diabetes, renal (e.g., normal renal test) or liver disease (e.g., liver function test was not higher than two times of normal range and gamma-glutamyl transferase (GGT) is less than 800 U/L), epilepsy, stroke
  • having history of alcohol withdrawal seizure or delirium based on clinical interview by attending psychiatrist
  • having moderate to severe alcohol withdrawal symptoms based on score >13 of the Clinical Interview for Withdrawal Alcohol Arlington (CIWA - Ar) at the time of recruitment
  • having cognitive impairment based on score \< 24 from the Mini Mental State Exam (MMSE)
  • having history of allergy to gabapentin
  • pregnancy or breast feeding.
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Gabapentin

    300 mg per day once daily before bedtime

    Drug: Gabapentin 300mg

  • Placebo comparator
    Control

    Capsule identical to the experimental arm, one tablet once daily before bedtime

    Drug: Placebo oral capsule

Interventions

  • DrugGabapentin 300mg
  • DrugPlacebo oral capsule
05

What researchers measure

Primary outcomes

  1. Frequency of heavy drinking

    Days per week of alcohol heavy drinking as measured by timelime followback (TLFB) (Sobell et al., 2001) - adapted Thai version. TLFB is the self-report form for a respondent to note days of heavy alcohol drinking, daily amount, and any symptoms related to alcohol drinking including days per week of alcohol drinking. The TLFB was given to the subjects after explaining how to record daily drinking behaviors and symptoms at home.

    Time frame: weekly for 12 weeks

Secondary outcomes

  1. Frequency of drinking

    Days per week of alcohol drinking as measured by timelime followback (TLFB) (Sobell et al., 2001) - adapted Thai version. TLFB is the self-report form for a respondent to note days of heavy alcohol drinking, daily amount, and any symptoms related to alcohol drinking including days per week of alcohol drinking. The TLFB was given to the subjects after explaining how to record daily drinking behaviors and symptoms at home.

    Time frame: weekly for 12 weeks

06

Study locations

1 site
  • Princess Mother National Institute on Drug Abuse and Treatment
    Pathum Thani, Thailand
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03274167
Lead sponsor
Chulalongkorn University
Collaborators
Princess Mother National Institute on Drug Abuse and Treatment
Responsible party
Rasmon Kalayasiri (Associate Professor, Chulalongkorn University) — Principal investigator
First posted
Sep 6, 2017
Start date
Jan 2012
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Sep 6, 2017

Study contacts

Sumnao Nilaban
principal investigator · Princess Mother National Institute on Drug Abuse and Treatment

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion